Table 1. Baseline characteristics of the studied subjects.
| RH (N=10) | |
|---|---|
| Clinical data | |
| Age (years) | 61.8 ± 8.5 |
| Gender (Female) | 40% (4) |
| BMI (Kg/m2) | 31.9 ± 5.9 |
| Type 2 Diabetes, (n) | 70% (7) |
| Non-white, (n) | 60% (6) |
| Anti-HA drugs | |
| Total number | 4.4 ± 0.7 |
| Diuretics, (n) | 100% (10) |
| Spironolactone, (n) | 50% (5) |
| β-blockers, (n) | 80% (8) |
| ACEis, (n) | 30% (3) |
| ARAs II, (n) | 70% (7) |
| CCBs, (n) | 90% (9) |
| Alpha-2 agonists, (n) | 12% (1) |
Data were expressed as mean and standard deviation, or percentage and absolute number. RH: resistant hypertension; BMI: body mass index; Anti-HA: antihypertensive; ACEis: angiotensin converting enzyme inhibitors; ARAs II: angiotensin II type I receptor antagonists; CCBs: calcium channel blockers.